Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18420909 | STENT DEVICE WITH STENT COVERING WITH REGIONS OF DIFFERING POROSITY | January 2024 | January 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18382907 | BARBED ROD FOR LINEAR TISSUE CLOSURE AND APPROXIMATION | October 2023 | August 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18282070 | LIGATION CLIP INCLUDING FLEXIBLE INSERT ASSEMBLY | September 2023 | June 2025 | Allow | 21 | 0 | 0 | Yes | No |
| 18154129 | MEDICAL INSTRUMENT SET, DELIVERY SYSTEM, AND EMBOLIC DEVICE DELIVERY MEDICAL SYSTEM | January 2023 | May 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18075164 | ULTRASONIC SCALPEL | December 2022 | February 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18049059 | OPTICALLY CLEAVED CATHETER COILING SYSTEM | October 2022 | March 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 17966779 | MEDICAL INSTRUMENT | October 2022 | March 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17936418 | MEDICAL INSTRUMENT SET, DELIVERY SYSTEM, AND EMBOLIC DEVICE DELIVERY MEDICAL SYSTEM | September 2022 | April 2025 | Abandon | 31 | 0 | 1 | No | No |
| 17913205 | MENISCAL REPAIR DELIVERY DEVICE | September 2022 | April 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17896309 | TWISTER IMPLANT DETACHMENT MECHANISM | August 2022 | January 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 17885618 | TREATMENT INSTRUMENT | August 2022 | October 2024 | Abandon | 26 | 2 | 0 | Yes | No |
| 17885278 | ULTRASOUND TREATMENT TOOL | August 2022 | January 2025 | Allow | 29 | 3 | 0 | Yes | No |
| 17707130 | SYSTEMS AND METHODS FOR EMBOLIC IMPLANT DEPLOYMENT | March 2022 | June 2025 | Abandon | 38 | 4 | 0 | Yes | No |
| 17695209 | ENDOVASCULAR COIL DEVICE FOR EMBOLIZATION OF BLOOD VESSELS | March 2022 | February 2024 | Abandon | 23 | 1 | 0 | Yes | No |
| 17685197 | FLEXIBLE FEATURE FOR EMBOLIC IMPLANT DEPLOYMENT | March 2022 | February 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17638588 | TISSUE ANCHOR AND RELATED METHODS | February 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17677963 | VASO-OCCLUSIVE DEVICE AND DELIVERY ASSEMBLY | February 2022 | October 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17673098 | STENT DEVICE WITH STENT COVERING WITH REGIONS OF DIFFERING POROSITY | February 2022 | October 2023 | Allow | 20 | 1 | 0 | Yes | No |
| 17671054 | BARBED ROD FOR LINEAR TISSUE CLOSURE AND APPROXIMATION | February 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17627716 | PACIFIER | January 2022 | October 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17569620 | Delivery and Detachment System Imposing a Friction Force on a Securement Wire to Minimize Movement of an Implantable Intravascular Device | January 2022 | October 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17566287 | IMPLANT DETACHMENT SYSTEMS WITH A MODIFIED PULL WIRE | December 2021 | June 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17564764 | SYSTEMS AND METHODS FOR EMBOLIC IMPLANT DEPLOYMENT | December 2021 | January 2025 | Abandon | 36 | 3 | 1 | Yes | No |
| 17564914 | PULL WIRE DETACHMENT FOR INTRAVASCULAR DEVICES | December 2021 | September 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17558691 | METHODS FOR CLOSING A WOUND | December 2021 | September 2024 | Allow | 33 | 3 | 0 | Yes | No |
| 17551039 | Knotless Locking Device with Directional Tensioning and Locking | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17540057 | Re-Tensionable Suture Anchor System and Related Methods | December 2021 | April 2024 | Allow | 28 | 2 | 0 | No | No |
| 17453037 | MEDICAL SYSTEMS, DEVICES, AND RELATED METHODS | November 2021 | February 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17447396 | SUTURE PASSING DEVICE | September 2021 | December 2023 | Abandon | 27 | 1 | 0 | Yes | No |
| 17436835 | HYDRAULIC MEDICAL INSTRUMENT AND SURGERY ASSISTING ROBOT | September 2021 | March 2024 | Allow | 30 | 0 | 0 | Yes | No |
| 17407331 | SOFT ANCHORS HAVING INCREASED ENGAGEMENT BETWEEN DEPLOYMENT SUTURES AND SLEEVE | August 2021 | April 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17428069 | SURGICAL INSTRUMENT AND OPERATION ROBOT | August 2021 | February 2025 | Allow | 43 | 1 | 0 | No | No |
| 17384726 | Mechanical Detachment Systems | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17351295 | SHEET-SHAPED OBJECT ATTACHING DEVICE | June 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17323578 | METHOD AND APPARATUSES FOR ACCESSING AND/OR MODIFYING A TARGET PATIENT TISSUE SITE | May 2021 | January 2024 | Allow | 32 | 0 | 0 | Yes | No |
| 17293226 | SYSTEMS AND METHODS OF ENDOSCOPIC INSTRUMENTS WITH ARTICULATING END | May 2021 | April 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17306412 | LEAFLET GRASPING AND CUTTING DEVICE | May 2021 | March 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17285517 | VITRECTOME ACTUATOR | April 2021 | March 2025 | Allow | 47 | 4 | 0 | No | No |
| 17272943 | OPERATION SYSTEM, SURGICAL SYSTEM, OPERATION INSTRUMENT, MEDICAL DEVICE, AND EXTERNAL FORCE DETECTION SYSTEM | March 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17273050 | DUAL-MOTOR CLIP APPLICATOR | March 2021 | March 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17191613 | PRE-SHAPED TISSUE ANCHORS AND NEEDLES FOR TISSUE ANCHOR DEPLOYMENT | March 2021 | December 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17190964 | TREATMENT DEVICE | March 2021 | November 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17271464 | A DELIVERY SYSTEM FOR IMPLANTING A MEDICAL DEVICE | February 2021 | September 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17270901 | A fault-tolerant endovascular inflation device | February 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17270343 | FLUID FLOW METAL SLEEVE | February 2021 | April 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17155585 | DEVICES, SYSTEMS, AND METHODS FOR OTOLOGY | January 2021 | March 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 16965849 | EAR TREATMENT INSTRUMENT | January 2021 | June 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17260578 | A SUTURE MEMBER, SUTURING NEEDLE AND SUTURING DEVICE | January 2021 | February 2025 | Allow | 49 | 4 | 0 | No | No |
| 17119549 | MEDICAL TREATMENT TOOL | December 2020 | October 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16976659 | PROSTHETIC DEVICE ADHESIVE SYSTEM | August 2020 | June 2024 | Allow | 46 | 3 | 0 | No | No |
| 17000289 | DEVICE SET DESIGNED FOR PCNL SURGERY | August 2020 | June 2024 | Allow | 46 | 4 | 0 | Yes | No |
| 16947202 | DEVICE AND METHOD FOR TREATMENT OF HEMORRHOIDS | July 2020 | January 2024 | Allow | 42 | 2 | 0 | Yes | Yes |
| 16802077 | RETENTION ANCHOR FOR SURGICAL ACCESS DEVICES | February 2020 | December 2024 | Allow | 57 | 4 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JAFFRI, ZEHRA.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JAFFRI, ZEHRA works in Art Unit 3771 and has examined 52 patent applications in our dataset. With an allowance rate of 67.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner JAFFRI, ZEHRA's allowance rate of 67.3% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JAFFRI, ZEHRA receive 1.48 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JAFFRI, ZEHRA is 33 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +48.0% benefit to allowance rate for applications examined by JAFFRI, ZEHRA. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.7% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 59% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 20% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 5% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 41% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 41% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.